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Abstract
Background: n-3 fatty acids and lifestyle also are closely related to risk of CVD. Most Koreans have higher fish
consumption than people of Western populations. However, little is known about the recommended value of
omega-3 index in Korean patients with acute ST-elevation myocardial infarction (STEMI) taking statins. Here, we
tested the hypothesis that lower omega-3 fatty acids and/or smoking are associated with acute STEMI, even
though patients with dyslipidemia who were taking statins and who attained their LDL-C goals.
Methods: We conducted a case-control study in which omega-3 fatty acids and lifestyle factors were determined
in 24 consecutive Korean patients taking statins with angiographically confirmed acute STEMI and 68 healthy
controls without acute STEMI. The omega-3 index was calculated by the sum of eicosapentaenoic acid and
docosahexaenoic acid in erythrocyte membranes. Multivariable adjusted regression analysis was used to assess
independent associations between acute STEMI, omega-3 index, and lifestyle factors after adjusting for age, sex,
and body mass index (BMI).
Results: The mean age of total subjects was 59.9 years, and 57.6% of the subjects were male. The omega-3 index
was significantly lower in cases (8.83%) than controls (11.13%; P < 0.001); however, total trans-fatty acids were not
different between the two groups. The omega-3 index was inversely associated with odds for being a case (OR
0.16 (95% CI 0.03-1.14); P = 0.047), while smoking was positively associated with odds for being a case (OR 6.67
(95% CI 1.77-25.23); P = 0.005) after adjusting for all confounding variables.
Conclusion: This study shows that relative to controls, acute STEMI cases are more likely to be smokers and to
have a lower omega-3 index, even though the cases were taking statins. An omega-3 index of at least 11% and
abstinence from smoking are associated with cardioprotection for Koreans.
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Background
Cardiovascular disease (CVD) is one of the most com-
mon causes of mortality and morbidity across the globe
[1]. Studies that have focused on the prevention of cor-
onary heart disease (CHD) have reported that lifestyle
modifications such as smoking cessation, adequate alco-
hol consumption, exercise, stress reduction, weight
control, and diet are preventable factors of CVD [2-5].
Dietary n-3 polyunsaturated fatty acids (PUFA) such as
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), which are found in fish meat and fish oil, have
also been shown to protect against CVD during the past
three decades [6]. Since the first observation of Green-
land Eskimos in 1970, epidemiologic studies have sug-
gested that n-3 PUFA may play a role in the prevention
of CVD [7]. Several large-scale intervention studies have
reported that n-3 PUFA from fish or fish-oil supple-
ments reduces the rates of all-cause mortality, cardiac
and sudden death, and possibly stroke [8]. In addition,
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any medium, provided the original work is properly cited.n-3 fatty acids are considered to have several beneficial
effects, including reduction of inflammation [9], preven-
tion of blood clotting [10], decrease in triglycerides [11],
and lowering of blood pressure [12].
T h es u mo fE P A+D H Ai ne r y t h r o c y t e( R B C )m e m -
brane fatty acids is a good reflection of systemic n-3
PUFA status and is called the omega-3 index, which is
expressed as a percent of total identified fatty acids [13].
Previous studies have shown that Asians with higher fish
consumption had a greater omega-3 index, and further-
more, they had a higher omega-3 index than the recom-
mended value of 8% or greater to prevent CHD for
Western people. The omega-3 index in healthy Koreans
and Japanese is about 11-12 and 7-11%, respectively,
while it is around 4% in people from Western popula-
tions [13-15]. Nevertheless, CVD is becoming more pre-
valent in Korea and is now a leading cause of death [16],
although the prevalence of CVD in Korea remains lower
than that in the US and other Western populations. A
study of more than 40,000 middle-aged Japanese people
revealed that a higher fish intake is associated with a sub-
stantially reduced risk of CHD compared to the recom-
mended amount of fish intake in Western countries [17].
A recent meta-analysis of 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) in primary pre-
vention showed that the lipid profile was improved in all
14 trials of about 34,000 people who had no evidence of
existing CVD, but the benefits of statins for the primary
prevention of CVD may differ according to cardiovascular
risk [18]. Recently, several studies confirmed that prescrip-
tion omega-3 fatty acids administered in statin-treated
patients with hypertriglyceridemia was superior to statins
alone in improving lipid parameters [19-21]. However, it
remains unclear whether omega-3 index is different
between controls and patients with recent myocardial
infarction (MI) taking statins in Koreans, who consume
more fish than Western populations. The purpose of the
present study was to compare fatty acid composition of
RBCs, the omega-3 index, and lifestyle behaviors between
controls and patients with acute ST-elevation MI (STEMI)
who attained their LDL-C goals with statins.
Materials and methods
Study design and subjects
This was a cross-sectional, case-control study. The study
protocol was approved by the Institutional Review Board
of Pusan National University Hospital, and informed
written consent was obtained from all subjects before
participating.
Subjects were divided into 2 subgroups: a case group
of 24 patients with first acute MI, who were consecu-
tively recruited from the Coronary Care Unit at Pusan
National University Hospital (Busan, Korea) and a con-
trol group of 68 apparently healthy persons with no
history or clinical evidence of CVD, hypertension, or
diabetes mellitus as well as acute MI, who were not tak-
ing statins and recruited from the Health Promotion
Center during the course of annual health check-up
visits.
Emergency coronary angiography was performed using
the percutaneous femoral approach within the first 12 h
after the onset of typical ischaemic-type chest pain. Acute
STEMI was defined according to consensus documents of
American College of Cardiology and European Society of
Cardiology as typical ischaemic-type chest pain, typical
rise and fall of biochemical markers (troponin or CK-MB),
and electrocardiogram showed new ST segment elevation
or pathologic Q waves. The number and severity of coron-
ary artery stenosis were documented through coronary
angiography. All patients were already taking statins due
to dyslipidemia with/without hypertension or type 2 dia-
betes mellitus. Exclusion criteria included abnormal liver
or renal function (ie, serum aminotransferase activity > 40
IU/L and serum creatinine concentrations > 1.2 mg/dL);
cancer (diagnosed clinically or by anamnesis); extreme
weight loss or gain over the previous 6 months; thyroid or
pituitary disease; infection determined by medical ques-
tionnaire and complete blood count; and connective tissue
disease.
Clinical, sociodemographic, lifestyle, and medication
information such as oral hypoglycemic agents, insulin,
lipid-lowering agents, and anti-hypertensive or estrogen
agents were obtained from all study subjects. Subjects tak-
ing a supplement containing n-3 fatty acids were excluded.
Measurements
Height and body weight of subjects were measured using a
digital scale, and the body mass index (BMI) was calcu-
lated as weight (kg)/height (m
2). Resting blood pressure
was measured using an automatic sphygmomanometer
(BP203RV-II; Nippon Colin, Komaki, Japan) after > 10
min at rest in a sitting position.
Peripheral blood was drawn from patients on day 1 (at
the time of admission) after the onset of infarction and
controls after an overnight fast of at least 8 h for measure-
ments of serum total cholesterol, triglycerides, high density
lipoprotein (HDL)-cholesterol, low density lipoprotein
(LDL)-cholesterol, and glucose. All biochemical analyses
were carried out within 2 hr of blood sampling using an
autoanalyzer (model 7600-110; Hitachi Corp., Tokyo,
Japan) and commercially available kits. RBCs were used
for fatty acid analysis. Boron trifluoride methanol-benzene
(BI252; Sigma-Aldrich, BI252; Sigma-Aldrich, St. Louis,
MO, USA) was added to RBCs, and samples were methy-
lated for 10 min at 100°C. Fatty acid methyl esters were
analyzed by gas chromatography (Shimadzu 2010 AF;
Shimadzu Scientific Instrument, Tokyo, Japan) with a
100 mm × 0.25 mm SP2560 capillary column (Supelco;
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(GLC-727; Nu-Check Prep, Elysian, MN, USA) was used
for identifying fatty acids and correcting inter-assay varia-
tion. In the standard 18: 1t peak was the mixture of 18:
1n-12t, C18: 1n-9t, and 18: 1n-7t, while the 18: 2n-6t peak
contained 18: 2n-6tt, 18:2n-6tc, and 18:2n-6ct. Fatty acids
for which no standards were available are reported as uni-
dentified fatty acids. When the percentage of fatty acid
was less than 0 5, it is recorded as a trace. The omega-3
index was calculated as the sum of EPA and DHA in
RBCs and expressed as percentage of total fatty acids in
the RBC membrane [22]. The quality-control sample was
composed of pooled RBCs, and the coefficient of variation
was 6.2%.
The usual dietary intakes were assessed using a semi-
quantitative food frequency questionnaire (FFQ). A trained
dietitian interviewed the participants regarding the average
frequency of consumption and portion size of each food
weekly. FFQ was designed to assess the habitual diet dur-
ing the previous seven days, the daily intakes of food
groups, energy, and nutrients were computed using an
analysis program, and weekly total fish intakes were
obtained from all subjects. Alcohol consumption and
smoking status were assessed using a self-reported ques-
tionnaire. Data on alcohol intake and smoking habits were
obtained by interview. Subjects were divided into two
groups by the amount of alcohol consumption: non-drin-
ker, 0-180 g/week; and drinker, > 180 g/week. Based on
WHO guidelines, smoking status was divided into three
categories: current smoker, ex-smoker, and non-smoker.
Statistical analysis
The D’Agostino-Pearson test was used to test the nor-
mality of all continuous variables. Results are shown as
mean and s.d. because variables were all normally distrib-
uted. The two sample t-test and chi-square test were
applied for continuous and categorical variables, respec-
tively. Correlation between variables was tested by partial
correlation coefficients after adjusting for age and sex.
Multivariable adjusted regression analysis was used to
assess independent associations between acute STEMI,
quartiles of the omega-3 index, and lifestyle factors after
adjusting for age, sex, and BMI. Statistical analysis was
obtained using the Statistical Package for Social Science
13.0 for Windows (SPSS, I n c . ,C h i c a g o ,U S A ) .A l l
p values were two-tailed, and a p value of < 0.05 was con-
sidered statistically significant.
Results
General characteristics of study subjects
The basal characteristics of subjects are shown in Table 1.
Among all acute STEMI patients having multi-vessel cor-
onary artery disease, 12 (50.0%) had one-vessel disease, 5
(20.8%) had two-vessel disease, and 7 (29.2%) had three-
vessel disease. The mean age of total subjects was 59.9 ±
9.1 years, and 57.6% of the subjects were male. Looking at
the case-control comparison, the case group had signifi-
cantly lower levels of total cholesterol, LDL-cholesterol,
HDL-cholesterol, and systolic blood pressure and higher
levels of high sensitivity C-reactive protein than did the
control group. However, there was no significant differ-
ence in age, gender distribution, BMI, triglyceride, and dia-
stolic blood pressure between the two groups. There was a
significantly higher percentage of current smokers in the
case group than in the control group, while there was no
difference in the proportion of alcohol drinkers between
the two groups. All cases had dyslipidemia with/without
hypertension or diabetes mellitus and received statins.
RBC membrane fatty acid composition
Fatty acid composition of RBCs is presented in Table 2.
No difference was observed regarding the RBC membrane
contents of saturated fatty acids, PUFA, and total trans-
fatty acids between the case-control groups, but monoun-
saturated fatty acids (MUFA) of RBC were significantly
lower in cases than controls (P = 0.011). Among saturated
fatty acids, 18: 0 was lower in cases when compared to
that found in controls and 24: 0 was higher. In regard to
MUFA, 16: 1n-7t, 18: 1n-9, and 20: 1n-9 were significantly
higher in cases than controls, whereas 16: 1n-7 was lower.
Of RBC contents of PUFA, omega 6 fatty acids were sig-
nificantly higher in cases than in controls (P < 0.001),
while omega 3 fatty acids were lower (P = 0.008).
Table 1 Sociodemographic and clinical characteristics of
study subjects
Case (n = 24) Control (n = 68) p value
Age (years) 61.6 ± 11.6 59.3 ± 8.1 0.370
Men (%) 17 (70.8) 36 (52.9) 0.127
Body mass index (kg/m
2) 23.5 ± 2.8 24.0 ± 2.5 0.405
Total cholesterol (mg/dl) 159.0 ± 30.0 201.1 ± 38.8 < 0.001
Triglyceride (mg/dl) 123.3 ± 73.9 128.7 ± 62.8 0.731
HDL-cholesterol (mg/dl) 42.1 ± 10.8 52.9 ± 10.7 < 0.001
LDL-cholesterol (mg/dl) 81.4 ± 24.7 119.8 ± 34.7 < 0.001
Systolic BP (mm/Hg) 111.9 ± 18.7 124.3 ± 14.1 0.001
Diastolic BP (mm/Hg) 70.5 ± 13.0 76.0 ± 8.6 0.065
hs-CRP (mg/dl) 2.66 ± 3.50 0.13 ± 0.19 0.002
Co-morbidity
Hypertension 10 (41.7) 0 (0.0) < 0.001
Diabetes mellitus 12 (50.0) 0 (0.0) < 0.001
Dyslipidemia 24 (100.0) 0 (0.0) < 0.001
Fish intake (servings/week) 2.1 ± 2.1 3.1 ± 2.1 0.059
Alcohol drinker (%) 10 (41.7) 21 (30.9) 0.337
Current smoker (%) 11 (45.8) 10 (14.7) 0.002
Data are expressed as means ± SD or number (%).
HDL, high density lipoprotein; LDL, low density lipoprotein; BP, blood
pressure; hs-CRP, high sensitivity C-reactive protein.
p value by two sample t-test or chi-square test
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than in controls, but 18: 2n-6 and 20: 3n-6 were higher.
Cases had significantly lower RBC membrane contents of
20: 5n-3 (EPA), 22: 5n-3, and 22: 6n-3 (DHA) than did
controls. The omega 6/omega 3 ratio and arachidonic
acid/EPA ratio were significantly higher, but the omega-3
index was significantly lower in cases than in controls (P =
0.002).
Correlation between acute STEMI, alcohol drinking,
smoking, BMI, and RBC membrane fatty acid composition
The partial correlation coefficients between acute
STEMI, alcohol drinking, smoking, BMI, and RBC mem-
brane fatty acid composition are shown in Table 3.
There was a negative correlation between acute STEMI
and quartiles of the omega-3 index (r = -0.585, P <
0.001), BMI (r = -0.272, P = 0.027), and MUFA (r =
-0.299, P = 0.015), while there was a borderline
correlation between acute STEMI and fish consumption
(r = -0.242, P = 0.050) after adjusting for age and gen-
der. However, acute STEMI correlated positively with
smoking (r = 0.366, P = 0.003) and the arachidonic
acid/EPA ratio (r = 0.309, P = 0.012) after adjusting for
age and gender.
Association of the omega-3 index, smoking, and odds for
being acute STEMI
Study subjects were categorized into four groups
according to the omega-3 index. Multivariable adjusted
regression analysis showed that the omega-3 index, age;
the omega-3 index was inversely associated with odds
for being a case (OR 0.16 (95% CI 0.03-1.14); P =
0.047), while smoking was positively associated with
odds for being a case (OR 6.67 (95% CI 1.77-25.23); P =
0.005) after adjusting for age, gender, BMI, alcohol
drinking (Table 4).
Table 2 Fatty acid composition of erythrocytes in subjects
Fatty acids (weight %) Case (n = 24) Control (n = 68) p value*
Saturated fatty acids 39.45 ± 6.45 40.12 ± 4.90 0.600
Myristic (14:0) 0.77 ± 0.41 0.65 ± 0.43 0.227
Palmitic (16:0) 24.31 ± 3.44 23.63 ± 3.30 0.390
Stearic (18:0) 13.71 ± 3.64 15.34 ± 2.79 0.025
Lignoceric (24:0) 0.67 ± 0.47 0.43 ± 0.51 0.048
Monounsaturated fatty acids 17.09 ± 1.91 18.22 ± 1.81 0.011
trans-Palmitoleic (16:1n-7t) 0.60 ± 0.55 0.36 ± 0.42 0.031
Palmitoleic (16:1n-7) 1.11 ± 0.48 4.40 ± 2.87 < 0.001
trans-Oleic (18:1n-9t) 0.84 ± 0.41 0.58 ± 0.65 0.071
Oleic (18:1n-9) 14.65 ± 1.70 12.96 ± 2.43 0.002
Eicosenoic (20:1n-9) 0.79 ± 0.50 0.31 ± 0.37 < 0.001
Nervonic (24:1n-9) 0.54 ± 0.45 0.36 ± 0.88 0.062
Polyunsaturated fatty acids 41.35 ± 7.36 40.01 ± 5.45 0.351
Omega-6 29.81 ± 5.01 26.05 ± 4.14 < 0.001
trans-Linoleic (18:2n-6t) 0.22 ± 0.17 0.57 ± 0.51 < 0.001
Linoleic (18:2n-6) 14.38 ± 4.59 10.54 ± 3.42 < 0.001
Gamma-linolenic (18:3n-6) 0.34 ± 0.18 0.27 ± 0.56 0.590
Eicosadienoic (20:2n-6) 0.33 ± 0.18 0.41 ± 0.48 0.425
Dihomo-GLA (20:3n-6) 1.72 ± 0.46 1.43 ± 0.38 0.003
Arachidonic (20:4n-6) 11.25 ± 3.07 11.25 ± 2.76 0.998
Adrenic (22:4n-6) 1.29 ± 0.60 1.53 ± 0.61 0.101
Docosapentaenoic (22:5n-6) 0.51 ± 0.30 0.48 ± 0.61 0.753
Omega-3 11.54 ± 3.58 13.96 ± 3.86 0.008
Alpha-linolenic (18:3n-3) 0.77 ± 0.43 0.60 ± 0.66 0.148
Eicosapentaenoic (20:5n-3) 1.80 ± 0.65 2.53 ± 0.96 < 0.001
Docosapentaenoic (22:5n-3) 1.93 ± 0.73 2.64 ± 0.91 0.001
Docosahexaenoic (22:6n-3) 7.03 ± 2.54 8.61 ± 2.57 0.011
n-6/n-3 2.79 ± 0.83 2.07 ± 0.86 0.001
Omega-3 index 8.83 ± 3.00 11.13 ± 3.08 0.002
AA/EPA 6.88 ± 2.84 5.07 ± 2.20 0.002
Total trans fatty acids 1.51 ± 0.68 1.39 ± 0.86 0.527
*By two sample t-test; Omega-3 index, docosahexaenoic acid + eicosapentaenoic acid %; AA, arachidonic acid; EPA, eicosapentaenoic acid
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Statins are well-known as the first-line drugs in the treat-
ment of hyper-LDL cholesterolemia. Large-scale, prospec-
tive, randomized clinical trials have demonstrated that
statins improve clinical cardiovascular outcomes and
reduce mortality in both primary and secondary preven-
tion [18]. However, in the real world, despite that clinical
evidence, CHD including acute MI can occur even among
dyslipidemia patients currently taking a statin with an
LDL goal of less than 100 mg/d [23]. Therefore, combin-
ing omega-3 fatty acids with a statin induces further trigly-
ceride reduction for patients with high triglyceride levels
despite achieving target LDL cholesterol goals. However,
little is known about further prevention of cardiovascular
events in hypercholesterolemia patients without hypertri-
glyceridemia, especially with the addition of fish oil cap-
sules to statin therapy. A study did report, however, that
there was a further decrease in nonfatal coronary events
or unstable angina in patients with hypercholesterolemia,
especially in secondary prevention with the use of statins
and EPA in combination therapy [24]. This was the first
study to show an additional clinical benefit of long-term
combination therapy with omega-3 fatty acids and statins
without serious adverse effects compared to statins only.
However, this trial was not designed as a double-blind
study. Also, unfortunately, the study did not show RBC
fatty acid composition, investigated only EPA and not a
DHA effect on coronary events, and revealed no additional
benefit for acute MI.
Omega-3 fatty acids are known to cause improvement in
lipid profiles without inducing serious hepatotoxicity or
myopathy. Unlike previous studies, our study was specifi-
cally designed to evaluate the fatty acid composition of
RBC and lifestyle factors such as alcohol consumption and
smoking status in patients who developed acute STEMI,
although they were taking statins and had achieved their
LDL cholesterol control. The findings of this study can
give us better understanding of the effectiveness and lim-
itation of statin use for primary prevention of acute MI.
In the present study, the average omega-3 index in
healthy controls was about 11%, which was similar to fig-
ures from previous studies in Koreans [14,25], and
slightly higher than those reported by previous studies
performed in Japan [26,27]. Recent studies have shown
that the Japanese have an omega-3 index of 7-11%, and
the index tends to rise along with increasing age [26,27].
Our study did not show a correlation between omega-3
index and age.
Recently, two case-control studies were conducted to
reveal the omega-3 index of RBCs in patients with acute
MI or metabolic syndrome in Korea. One study found
that patients with acute MI have a lower omega-3 index
(9.6%) in comparison to healthy controls, and total
trans-fatty acids are associated with an increased risk of
MI. However, the result did not have adequate statistical
power due to a wide confidence interval of the odds
ratio of MI risk estimate. The other study reported that
Table 4 Multivariate analysis of the odds for being a case
by quartiles of the Omega-3 Index
Acute myocardial infarction
Variables Odds ratio (p value) 95% C.I.
Omega-3 index (%)
1
st quartile (< 8.11)* 6.383 (0.047) 1.022 - 39.853
2
nd quartile (8.11-11.00) 2.032 (0.471) 0.072 - 14.001
3
rd quartile (11.00-13.05) 2.982 (0.258) 0.105 - 19.823
4
th quartile (> 13.05) 1.000
Age* 1.073 (0.032) 1.006 - 1.144
Sex 1.301 (0.701) 0.340 - 4.980
Body mass index 1.019 (0.866) 0.822 - 1.262
Alcohol drinker 1.466 (0.568) 0.378 - 5.894
Current Smoker* 6.673 (0.005) 1.765 - 25.229
*p < 0.05, Test for trend across quartiles of Omega-3 index (P = 0.01).
Table 3 Correlation between acute myocardial infarction, alcohol drinking, smoking, body mass index, and
erythrocyte membrane fatty acid composition
Variables Acute MI Omega-3 index
Omega-3 index -0.585 (< 0.001)
Alcohol drinking -0.004 (0.973) -0.121 (0.333)
Smoking 0.366 (0.003) -0.220 (0.076)
Body mass index -0.272 (0.027) 0.293 (0.017)
Fish intake (servings/week) -0.242 (0.050) 0.284 (0.021)
Total saturated fatty acids -0.049 (0.693) -0.424 (< 0.001)
Total monounsaturated fatty acids -0.299 (0.015) -0.213 (0.086)
Total polyunsaturated fatty acids 0.080 (0.503) 0.499 (< 0.001)
Arachidonic acid/eicosapentaenoic acid ratio 0.309 (0.012) -0.473 (< 0.001)
Total trans fatty acids 0.117 (0.350) -0.150 (0.231)
By partial correlation coefficient after adjustment for age and gender
Data are expressed as correlation coefficients (p value).
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(12.4%) have similar omega-3 indices. In the present
study, we found that patients who experienced acute
STEMI, even though they were taking statins and had
achieved their LDL cholesterol control goal, had an
omega-3 index of 8.8%, which was significantly lower
than that of controls (11.1%), while no difference in
total trans-fatty acids was observed between the two
groups. Previous studies have provided inconsistent data
on whether trans fat intakes are associated with MI risk
according to levels of intake [28-30]. On the other hand,
the present study found that omega-6 fatty acids such as
linoleic acid were increased in patients with acute
STEMI compared to controls, which was in accordance
with a previous study [31]. Linoleic acid was frequently
inversely associated with risk for coronary heart disease
events in Western people [32]. However, the present
study found that omega-6 fatty acids such as linoleic
acid were increased in patients with acute STEMI com-
pared to controls. Previous studies from Korea and
Japan showed that there were no differences of linoleic
acid level between MI cases and controls [25,33].
Although it is not yet known why, possible mechanisms
underlying the ethnic difference in linoleic acid concen-
trations include differences in fat distribution, fatty acid
interactions with genetic polymorphisms, and diet.
Replication studies with larger sample size would be
needed to confirm our study results.
The American Heart Association recommends that
healthy people should eat two servings of a variety of
(preferably oily) fish per week [11]. The present study
showed an association between fish consumption and the
omega-3 index (r = 0.269, P = 0.026), although two sam-
ple t-test revealed only a borderline difference of average
fish consumption (servings/week) between cases and
controls (2.1 vs. 3.1, P = 0.059), although the consump-
tion was greater than that in most Western populations.
A Japanese study also showed that a very high level of
fish intake was significantly associated with a lower risk
of nonfatal CHD [17].
Harris et al. [13] suggest the omega-3 index (EPA +
DHA as a percent of total fatty acid in RBC membranes)
as a novel risk factor for CHD. The studies have shown
that a higher omega-3 index than a value of 8-10% is
desirable for its cardio-protective benefits, because of the
relationship between a lower average omega-3 index and
the development of CHD in Caucasians [13,22]. Interest-
ingly, Korean patients with acute STEMI already had an
omega-3 index of 8%, which is a cardio-protective goal
for Western people. Therefore, we suggest that a higher
cut-off point of omega-3 index than 8-10% for preventing
CHD is needed, and an omega-3 index of 11% or above
could be appropriate in Korea. This discrepancy between
Korean and Western people could be explained in large
part by the fact that most Korean people have higher fish
consumption than people of Western populations. Kor-
ean consumes fish species such as mackerel, salmon
which are very high in omega-3 [34]. In addition, there
m a yb ee t h n i cd i f f e r e n c e si nt h et h r e s h o l do fo m e g a - 3
index and underlying mechanism of development of
CHD. Using multivariable adjusted regression analysis,
our study showed that lower omega-3 index was inde-
pendently associated with acute STEMI after adjusting
for age, sex, and BMI. Subjects in the lowest quartile of
omega-3 index was positively associated with almost six
times odds for being a case, even after adjusting for all
confounding variables, than the highest quartile subgroup
(Table 4). That finding is concordant with previous case-
control studies about EPA and DHA levels that found
significantly lower EPA and DHA in patients with acute
coronary syndrome compared to healthy control people
[29,35]. A case-control follow-up study also provides evi-
dence of a plasma concentration of EPA and DPA asso-
ciated with a lower incidence of nonfatal MI among
American women [30], despite their current lower fish
intake than that of typical Korean and Japanese people.
Cigarette smoking is an important risk factor for cere-
bro-cardiovascular diseases. Epidemiologic, clinical, and
experimental data have revealed that smoking is pro-
thrombotic, atherogenic, and causative factors in the
development of CHD [36]. In the present study, we also
f o u n dt h a ts m o k i n gw a sam a j o ra s s o c i a t e df a c t o rf o r
acute STEMI development in patients taking statins who
had achieved their goal LDL cholesterol. Our results were
consistent with a previous study using Japanese data that
revealed an association of cigarette smoking with CVD
mortality in patients, despite their lower total cholesterol
level [37]. The relationship between omega-3 index and
smoking status is a controversial topic [38]. In additional
analysis, we found no difference in the omega-3 index
between smokers and non-smokers within each group
(data not shown).
There is no single cause for CHD. CVD is caused by a
constellation of risk factors, including environmental fac-
tors, such as sedentary lifestyle, genetic predisposition,
advancing age, smoking, an atherogenic diet, and under-
lying conditions or diseases including insulin resistance
or type 2 diabetes, hypertension, and dyslipidemia. In this
view, interestingly, the present study showed that smok-
ing, a lower omega-3 index, and advancing age together
among those factors may work together to cause acute
STEMI despite statin-induced low LDL cholesterolemia.
Another Korean study also reported that, compared to
survivors, non-survivors of acute MI had a lower level of
total cholesterol, triglycerides, and LDL-cholesterol,
while the opposite was observed with plasma omega-3
fatty acids [39]. However, the researchers did not explain
why non-survivors from acute MI had lower lipid levels
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Page 6 of 8than survivors. It is obvious, however, that certain cardio-
vascular events still occur even among patients reaching
target levels of LDL-cholesterol [30,35]. Therefore, rela-
tive to controls, STEMI cases are more likely to be smo-
kers and to have a lower omega-3 index, even though the
LDL cholesterol target is achieved with a statin in the
cases with dyslipidemia. Patients should be asked to quit
smoking and eat more fish or take omega-3 supplements
as well as reach their LDL-cholesterol target on a statin.
Our study is limited by its cross-sectional study
design. Further investigation with a cohort study is war-
ranted. Another limitation is the wide confidence inter-
val due to a relatively small sample size. Koreans usually
have a fish intake that is several times higher than Wes-
tern people, which limits the generalizability of those
results to other population groups.
In summary, subjects with acute STEMI had a lower
omega-3 index and higher smoking rate after adjusting
for age, gender, and BMI than controls, although they
are currently receiving a statin with an LDL goal of less
than 100 mg/d and normal triglyceride levels. Neverthe-
less, acute STEMI patients have an omega-3 index of
8.8% that is higher than that of people of Western
populations. This means that the cut-off point for the
omega-3 index for preventing CVD might be tailored
for the Korean population. Thus, at present, we suggest
a suitable level of an omega-3 index of 11% or above for
prevention of coronary artery disease in the Korean
population. However, replication studies with a larger
sample size are needed to confirm our first stage study
results for current practice in the field.
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